> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Warns Telehealth Firms on Compounded GLP-1 Marketing
- URL: https://www.fdaweb.com/fda-warns-telehealth-firms-on-compounded-glp-1-marketing/
- Published: 2026-06-15T12:00:00.000Z
- Updated: 2026-09-14T13:41:09.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161310

FDA is escalating its scrutiny of telehealth companies marketing compounded drugs, warning that some firms are making false or misleading claims about compounded GLP-1 weight-loss treatments and other medications that could mislead patients and violate federal law. An [FDA notice](https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs?ref=fdaweb.com) notes that the agency has issued Warning Letters to telehealth companies over promotional practices involving compounded drugs and reiterated that compounded products cannot be marketed as equivalent to FDA-approved medicines.

The warning comes amid explosive growth in online prescribing platforms offering compounded versions of popular obesity and diabetes treatments, including GLP-1 receptor agonists, as consumers seek alternatives to branded products such as Wegovy and Zepbound.

FDA says it is particularly concerned about telehealth companies presenting compounded drugs in ways that suggest they are FDA-approved, equivalent to approved products, or manufactured by FDA-approved facilities.

Among the practices cited by the agency are Web sites using branding that implies the telehealth company itself is the compounder, describing compounded drugs as generic versions of FDA-approved products, and claiming compounded medications have been evaluated by FDA for safety and effectiveness.

The agency also warned companies against claiming compounded products are "clinically proven" to achieve the same outcomes as FDA-approved drugs or suggesting that products are sourced from "FDA-approved" or "FDA-licensed" pharmacies or outsourcing facilities. FDA notes that it does not approve or license compounding facilities.

The latest action represents another step in the agency's broader effort to police the rapidly expanding market for compounded obesity medicines. During recent shortages of branded GLP-1 products, compounders emerged as a major source of alternative treatments, prompting increased regulatory attention as shortages eased and questions grew about marketing practices, product quality and patient safety.

While FDA did not identify specific companies in the notice, it directed stakeholders to search its [Warning Letter database](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters?ref=fdaweb.com) using the term "telehealth" to review recent enforcement actions. The agency says it will continue monitoring promotional materials and taking enforcement action when necessary. "The agency remains vigilant in its oversight of promotional materials and will continue to take actions to help protect patients from false or misleading claims by telehealth companies," it says.